Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURKOVAC Booster Phase 2b
NCT05210179Phase 2Completed
- Sponsor
- TÜSEB
- Start
- Jan 2022
- Primary completion
- Feb 2023
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of turkovac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by TÜSEB. Primary endpoints: Neutralizing Antibodies at Day 28, Pseudo-Neutralizing Antibodies at Day 28 and 2 more. Started Jan 2022; status: completed.
02
Drugs
turkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05210179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210179.